Physician profile
David S Cheng
NPI 1104892652
$9,391.68
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,115 · 2020: $2,233 · 2021: $4,460 · 2022: $1,528 · 2023: $25.53 · 2024: $30.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $56.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $56.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $1,625.42 | 2019-2022 | |
| Novo Nordisk INC | $1,065.71 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $778.61 | 2019-2022 | |
| Amgen INC. | $668.57 | 2019-2022 | |
| Gilead Sciences, INC. | $583.08 | 2019-2022 | |
| Lilly USA, LLC | $544.44 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $526.48 | 2019-2022 | |
| Glaxosmithkline, LLC. | $435.73 | 2020-2022 | |
| Seagen INC. | $388.29 | 2019-2023 | Adcetris |
| Pfizer INC. | $355.38 | 2020-2022 | |
| Janssen Biotech, INC. | $346.26 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $320.36 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $229.27 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $175.93 | 2020-2024 | Keytruda |
| Esperion Therapeutics, INC. | $153.61 | 2020-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Cheng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.